Table 2

Baseline characteristics of patients with CV outcomes

Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8Patient 9Patient 10
CV outcomeSVTSVTAFAFAF and flutterAtrial flutterNSVTNSVTNSVTMyocarditis
systolic dysfunction
Baseline ECGSRSRSRSRSRSRSR, VESR, unspecific flattened T waveSR
Age (years)74625773495552595060
GenderFFFFFFFFMF
SSc subsetlcSSclcSScdcSSclcSSclcSSclcSScdcSScdcSScdcSScdcSSc
ILDNoNoNoNoNoNoYesYesYesYes
MRSS6414226111809
ANAACAACAACAACAACAScl70Anti RoScl70Scl70
History of DUYesNoNoNoNoYesNoNoNoNo
NT-proBNP (pg/mL)1612881051273214132910538470
Hs-TnI (ng/L)35363131353225
  • ACA, anti-centromere antibody; AF, atrial fibrillation; ANA, antinuclear antibodies; CV, cardiovascular; dcSSc, diffuse cutaneous systemic sclerosis; DU, digital ulcers; hs-TnI, high-sensitivity troponin I; IcSSc, limited cutaneous systemic sclerosis; ILD, interstitial lung disease; MRSS, modified Rodnan skin score; NSVT, non-sustained ventricular tachycardia; NT-proBNP, N-terminal pro-brain natriuretic peptide; Scl70, anti-topoisomerase antibody; SR, sinus rhythm; SSc, systemic sclerosis; SVT, supraventricular tachycardia; VE, ventricular ectopics.